These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8601221)

  • 41. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection.
    Henrard DR; Daar E; Farzadegan H; Clark SJ; Phillips J; Shaw GM; Busch MP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):305-10. PubMed ID: 7788430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
    Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
    Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.
    Moss RB; Giermakowska WK; Wallace MR; Savary JR; Jensen FC; Carlo DJ
    AIDS; 2000 Nov; 14(16):2475-8. PubMed ID: 11101057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.
    Trabattoni D; Clivio A; Bray DH; Bhagat L; Beltrami S; Maffeis G; Cesana E; Lowry P; Lissoni F; Kandimalla ER; Sullivan T; Agrawal S; Bartholomew R; Clerici M
    Vaccine; 2006 Feb; 24(9):1470-7. PubMed ID: 16221513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
    Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
    J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.
    Moss RB; Wallace MR; Steigbigel RT; Morrison SA; Giermakowska WK; Nardo CJ; Diveley JP; Carlo DJ
    Clin Exp Immunol; 2002 May; 128(2):359-64. PubMed ID: 11985528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.
    Valdez H; Smith KY; Landay A; Connick E; Kuritzkes DR; Kessler H; Fox L; Spritzler J; Roe J; Lederman MB; Lederman HM; Evans TG; Heath-Chiozzi M; Lederman MM
    AIDS; 2000 Jan; 14(1):11-21. PubMed ID: 10714563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Remune trials recruiting.
    PI Perspect; 1996 Sep; (No 19):17. PubMed ID: 11363901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
    J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
    Pontesilli O; Guerra EC; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber AC; Vella S; Ortona L; Aiuti F
    AIDS; 1998 Mar; 12(5):473-80. PubMed ID: 9543445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.
    Lind A; Sommerfelt M; Holmberg JO; Baksaas I; Sørensen B; Kvale D
    Scand J Infect Dis; 2012 Aug; 44(8):566-72. PubMed ID: 22339485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disease progression markers during asymptomatic phase of HIV-1 infected children with unimpaired CD4+ cell values: evaluation of repeat CD4+ cell evaluation vs. other immunological parameters.
    Chattopadhya D; Baveja UK; Bose M; Kumar A
    J Trop Pediatr; 2002 Dec; 48(6):340-7. PubMed ID: 12521275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Relationship Between HIV Antibody Titer, HIV Viral Load, HIV p24 Antigen, and CD4 T-cell Count Among Iranian HIV-positive Patients.
    Moradbeigi M; SeyedAlinaghi S; Sajadipour M; Dadras O; Shojaei E; Ahmadi P; Bayanolhagh S; Baesi K; Rasoolinejad M
    Infect Disord Drug Targets; 2020; 20(5):752-757. PubMed ID: 31682214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.
    Smith D; Gow I; Colebunders R; Weller I; Tchamouroff S; Weber J; Boag F; Hales G; Adams S; Patou G; Cooper DA;
    HIV Med; 2001 Oct; 2(4):272-5. PubMed ID: 11737409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals.
    Seth A; Yasutomi Y; Jacoby H; Callery JC; Kaminsky SM; Koff WC; Nixon DF; Letvin NL
    AIDS Res Hum Retroviruses; 2000 Mar; 16(4):337-43. PubMed ID: 10716371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive markers of AIDS: a follow-up of lymphocyte subsets and HIV serology in a cohort of patients with lymphadenopathy.
    Böttiger B; Morfeldt-Månson L; Putkonen P; Nilsson B; Julander I; Biberfeld G
    Scand J Infect Dis; 1989; 21(5):507-14. PubMed ID: 2511625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.